The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2022 | RE-MIND2: observational study comparing tafasitamab+lenalidomide to available therapies in R/R DLBCL
Grzegorz Nowakowski, MD, Mayo Clinic, Rochester, MI, outlines the design of RE-MIND2 (NCT04697160), an observational retrospective study comparing the outcomes of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with tafasitamab plus lenalidomide versus existing available therapies in clinical practice, explaining that the study showed that the combination of tafasitamab and lenalidomide compared favorably to other therapies. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
